CNTG
vs
S&P 500
CNTG
S&P 500
Over the past 12 months, CNTG has underperformed S&P 500, delivering a return of -59% compared to the S&P 500's +12% growth.
Stocks Performance
CNTG vs S&P 500
Performance Gap
CNTG vs S&P 500
Performance By Year
CNTG vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Centogene NV
Glance View
Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The company is headquartered in Rostock, Mecklenburg-Vorpommern and currently employs 808 full-time employees. The company went IPO on 2019-11-07. The company focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The firm provides the full spectrum of methods and technology for human genetics analysis. The company develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The firm operates in Germany and the United States.
